Global Hyperphosphatemia Therapeutics Market

Hyperphosphatemia Therapeutics Market Size, Share, Growth Analysis, By Product Type(Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2014 | Region: Global | Published Date: April, 2024
Pages: 157 |Tables: 66 |Figures: 75

Hyperphosphatemia Therapeutics Market Insights

Global Hyperphosphatemia Therapeutics Market size was valued at USD 3.1 billion in 2019 and is poised to grow from USD 3.3 billion in 2023 to USD 4.2 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

Hyperphosphatemia occurs when the blood contains an excessive amount of phosphate. This condition occurs in almost 90% of end-stage renal disease patients going through dialysis. Hyperphosphatemia therapeutics such as phosphate binders are used to reduce the gastrointestinal absorption of phosphorus. The most commonly prescribed phosphate binders are calcium salts, but these may produce hypercalcemia. Similarly, there are several phosphate binder drug classes used such as sevelamer, lanthanum carbonate, magnesium-based phosphate binders, and iron-based phosphate binders. The population with chronic kidney disease and cardiovascular disorders tends to have an abnormally high level of phosphate. Hyperphosphatemia is a significant cause of mortality and morbidity in people with chronic renal disorders. The kidney's failure to eliminate phosphate is the most frequent reason for rising phosphate levels. Numerous hyperphosphatemia therapy approaches have been researched and investigated to lessen the burden of the condition. To control and prevent hyperphosphatemia, numerous phosphate-lowering hyperphosphatemia therapy strategies have been used. Hyperphosphatemia is irregularly caused by a large transcellular movement of phosphate into the extracellular space, overwhelming the renal excretory capacity. Such transcellular movement frequently takes place in diabetic ketoacidosis, nontraumatic rhabdomyolysis, crush injuries, overwhelming systemic infections, tumor lysis syndrome. Hyperphosphatemia may also take place due to excessive oral phosphate administration, and, at times, with overuse of enemas carrying phosphate.

Additionally, rising incidence rates of hyperphosphatemia and rising demand for effective hyperphosphatemia treatment alternatives are the main drivers of the Market. For dialysis patients, maintaining an ideal phosphate level can be quite difficult. And occasionally, phosphate is completely removed from the body during dialysis, in which case patients must take phosphate binders to keep their phosphate levels stable. This might limit the global hyperphosphatemia therapeutics market growth.

US Hyperphosphatemia Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 3.1 billion

Largest Segment

Hospital Pharmacies

Fastest Growth

Hospital Pharmacies

Growth Rate

6.5% CAGR

Global Hyperphosphatemia Therapeutics Market 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Hyperphosphatemia Therapeutics Market Segmental Analysis

The Global Hyperphosphatemia Therapeutics Market is segmented by Product Type, Distribution Channel, and Region. Based on Product Type, the Hyperphosphatemia Therapeutics Market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. Based on Distribution channels, the Hyperphosphatemia Therapeutics Market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the Hyperphosphatemia Therapeutics Market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Hyperphosphatemia Therapeutics Market Analysis by Product Type

Based on Product Type, the market is segmented into Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, and Others. The sevelamer segment of the market held a significant share in the market in 2021. A shift in healthcare providers' choices away from calcium-based phosphate binders due to these products' drawbacks, including higher pill burden, risk of cardiovascular complications, and relatively lower absorption in elderly patients, is largely responsible for the increased demand for sevelamer-based phosphate binders in developed and underdeveloped economies.

Further, there has also been an increased demand for iron-based phosphate binders among medical professionals due to the lack of study on the long-term safety profile of sevelamer and other unique benefits of iron-based drugs. Along with the development of new generic and branded pharmaceuticals in this class by key players, this is boosting the availability of these medications in both developed and developing countries.

Hyperphosphatemia Therapeutics Market Analysis by Distribution Channel

Based on the distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with the highest share in 2021. This is attributed to sizable patient populations seeking dialysis treatment in medical facilities around the world. Additionally, rising economies with high treatment costs, like India, have seen a large increase in the number of dialysis patients in these countries. Consequently, segmental growth will be supported by a large number of patients using hospital facilities. Further, during the projection period, the online pharmacies segment is anticipated to expand at the fastest CAGR. The shift of the patient population toward e-commerce platforms for the purchase of medications for the treatment of hyperphosphatemia in major cities is the major aspect of this segmental growth.

Global Hyperphosphatemia Therapeutics Market By Distribution Channel, 2021 (%), 2023 (%)

To get detailed analysis on other segments, Request For Free Sample Report

Hyperphosphatemia Therapeutics Market Regional Insights

The Global Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.

Global Hyperphosphatemia Therapeutics Market By Geography, 2021 - 2028, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Hyperphosphatemia Therapeutics Market Dynamics

Hyperphosphatemia Therapeutics Market Driver

  • The increasing prevalence of chronic renal disease worldwide is one of the key factors propelling the market's growth. Due to its expanding global impact, it is predicted that by 2040, chronic kidney disease (CKD) would rank as the fifth most common cause of years lost globally. The overall number of individuals receiving dialysis has increased globally as a result of the rising prevalence of CKD. 785,883 Americans needed kidney transplants and dialysis in 2018, according to the National Kidney Foundation Inc. Of these people, dialysis was utilized to replace renal function in 554 338 cases. Nearly all dialysis-dependent renal failure patients experience hyperphosphatemia at some point in their lives. Additionally, according to the National Center for Biotechnology Information (NCBI), phosphate binders are used to treat 80–85% of dialysis patients who have hyperphosphatemia. Therefore, the market's growth during the forecast period will be greatly supported by the rising prevalence of chronic renal diseases.
  • The number of new drugs being released in developing nations is expected to increase the demand for the hyperphosphatemia therapeutics market. For instance, in April 2021, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) published favorable results. Results of phase-Ill research on Velphoro (PA211) in China showed it could lower serum phosphorus in CKD patients over the age of dialysis. Such launch and pipeline products of hyperphosphatemia therapeutics are likely to aid the market growth in the upcoming years.

Hyperphosphatemia Therapeutics Market Restraint

  • One of the main factors restraining the market's growth is poor treatment compliance among dialysis patients as a result of their heavy tablet load. For instance, a dialysis patient is typically expected to take 10 to 12 different types of drugs, according to a National Center for Biotechnology Information (NCBI) article. Nearly 80% of patients take four or more pills daily from phosphate binders, which can have negative side effects including gastrointestinal discomfort. Therefore, it is projected that these considerations will restrict CKD patients' use of phosphate binders, which will restrict the market's growth.

Request Free Customization of this report to help us to meet your business objectives.

Hyperphosphatemia Therapeutics Market Competitive Landscape

The Global Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the global Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology.

Hyperphosphatemia Therapeutics Market Top Player's Company Profiles

  • Sanofi Genzyme
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Vifor Pharma Management Ltd.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Pfizer Inc.
  • Relypsa, Inc.
  • Ardelyx, Inc.
  • Velphoro (Fresenius Medical Care AG & Co. KGaA)
  • Phoslyra (Fresenius Medical Care AG & Co. KGaA)
  • Renvela/Renagel (Sanofi Genzyme)
  • Fosrenol (Shire)
  • Kayexalate (Sanofi Genzyme)
  • Ferumoxytol (AMAG Pharmaceuticals, Inc.)
  • Etelcalcetide (Amgen Inc.)
  • Parsabiv (Amgen Inc.)
  • Patiromer (Relypsa, Inc.)
  • Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)

Hyperphosphatemia Therapeutics Market Recent Developments

  • In June 2022, Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced the initiation of its pivotal clinical bioequivalence (BE) study of Renazorb (lanthanum dioxycarbonate.) Renazorb is a novel phosphate-binding agent utilizing proprietary nanoparticle technology that is being developed by Unicycive for the treatment of hyperphosphatemia.
  • In April 2022, Ardelyx completed three successful Phase 3 pivotal trials and two additional Phase 4 clinical trials (OPTIMIZE and NORMALIZE) for XPHOZAH, an investigational, first-in-class, phosphate absorption inhibitor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Hyperphosphatemia Therapeutics Key Market Trends

  • A shift towards the adoption of non-phosphate binders is the key trend in the market. It is quite difficult to achieve ideal phosphate management in CKD patients receiving dialysis. The ability to manage phosphate levels in dialysis patients has not significantly improved despite the advancements in dialysis procedures throughout the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the development of novel hyperphosphatemia medicines and revising the treatment recommendations in order to improve the therapy choice for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3).

Hyperphosphatemia Therapeutics Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our business information services team that collects, collates, co-relates, and analyses the data collected by means of primary exploratory research backed by the robust secondary desk research.

According to our analysis, based on the region, the North American region dominated the global hyperphosphatemia therapeutics market over other regions. The dominance of North America can be attributed to increased income levels, the region by far being the market leader for medications for hyperphosphatemia, along with the advanced healthcare infrastructure. On the other hand, based on the segmentation, the Sevelamer-based phosphate binders segment held the most dominating share in the market attributing to the increasing prevalence of chronic and renal diseases across the globe.

Report Metric Details
Market size value in 2023 USD 3.1 billion
Market size value in 2031 USD 4.2 billion
Growth Rate 6.5%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Product Type
    • Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, Others
  • Distribution Channel
    • Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Sanofi Genzyme
  • Keryx Biopharmaceuticals, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Vifor Pharma Management Ltd.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Pfizer Inc.
  • Relypsa, Inc.
  • Ardelyx, Inc.
  • Velphoro (Fresenius Medical Care AG & Co. KGaA)
  • Phoslyra (Fresenius Medical Care AG & Co. KGaA)
  • Renvela/Renagel (Sanofi Genzyme)
  • Fosrenol (Shire)
  • Kayexalate (Sanofi Genzyme)
  • Ferumoxytol (AMAG Pharmaceuticals, Inc.)
  • Etelcalcetide (Amgen Inc.)
  • Parsabiv (Amgen Inc.)
  • Patiromer (Relypsa, Inc.)
  • Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Hyperphosphatemia Therapeutics Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Hyperphosphatemia Therapeutics Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Hyperphosphatemia Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Hyperphosphatemia Therapeutics Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Hyperphosphatemia Therapeutics Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Hyperphosphatemia Therapeutics Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hyperphosphatemia Therapeutics Market size was valued at USD 3.1 billion in 2019 and is poised to grow from USD 3.3 billion in 2023 to USD 4.2 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

The Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi Genzyme', 'Keryx Biopharmaceuticals, Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Vifor Pharma Management Ltd.', 'Amgen Inc.', 'F. Hoffmann-La Roche Ltd.', 'AstraZeneca plc', 'Pfizer Inc.', 'Relypsa, Inc.', 'Ardelyx, Inc.', 'Velphoro (Fresenius Medical Care AG & Co. KGaA)', 'Phoslyra (Fresenius Medical Care AG & Co. KGaA)', 'Renvela/Renagel (Sanofi Genzyme)', 'Fosrenol (Shire)', 'Kayexalate (Sanofi Genzyme)', 'Ferumoxytol (AMAG Pharmaceuticals, Inc.)', 'Etelcalcetide (Amgen Inc.)', 'Parsabiv (Amgen Inc.)', 'Patiromer (Relypsa, Inc.)', 'Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)'

The increasing prevalence of chronic renal disease worldwide is one of the key factors propelling the market's growth. Due to its expanding impact, it is predicted that by 2040, chronic kidney disease (CKD) would rank as the fifth most common cause of years lost globally. The overall number of individuals receiving dialysis has increased globally as a result of the rising prevalence of CKD. 785,883 Americans needed kidney transplants and dialysis in 2018, according to the National Kidney Foundation Inc. Of these people, dialysis was utilized to replace renal function in 554 338 cases. Nearly all dialysis-dependent renal failure patients experience hyperphosphatemia at some point in their lives. Additionally, according to the National Center for Biotechnology Information (NCBI), phosphate binders are used to treat 80–85% of dialysis patients who have hyperphosphatemia. Therefore, the market's growth during the forecast period will be greatly supported by the rising prevalence of chronic renal diseases.

A shift towards the adoption of non-phosphate binders is the key trend in the market. It is quite difficult to achieve ideal phosphate management in CKD patients receiving dialysis. The ability to manage phosphate levels in dialysis patients has not significantly improved despite the advancements in dialysis procedures throughout the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the development of novel hyperphosphatemia medicines and revising the treatment recommendations in order to improve the therapy choice for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3).

The Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Hyperphosphatemia Therapeutics Market

Product ID: SQSG35I2014

$5,300
BUY NOW GET FREE SAMPLE